Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 316

The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.

Invasive aspergillosis in patients with acute myeloid leukemia: a SEIFEM-2008 registry study

Open access
Pagano, L., Caira, M., Candoni, A., Offidani, M., Martino, B., Specchia, G., Pastore, D., Stanzani, M., Cattaneo, C., Fanci, R., Caramatti, C., Rossini, F., Luppi, M., Potenza, L., Ferrara, F., Mitra, M. E., Fadda, R. M., Invernizzi, R., Aloisi, T., Picardi, M., Bonini, A., Vacca, A., Chierichini, A., Melillo, L., de Waure, C., Fianchi, L., Riva, M., Leone, G., Aversa, F., Nosari, A.·2010·Haematologica

Abstract

BACKGROUND: The aim of this study was to evaluate prognostic factors, treatments and outcome of invasive aspergillosis in patients with acute myeloid leukemia based on data collected in a registry. DESIGN AND METHODS: The registry, which was activated in 2004 and closed in 2007, collected data on patients with acute myeloid leukemia, admitted to 21 hematologic divisions in tertiary care centers or university hospitals in Italy, who developed proven or probable invasive aspergillosis. RESULTS: One hundred and forty cases of invasive aspergillosis were collected, with most cases occurring during the period of post-induction aplasia, the highest risk phase in acute myeloid leukemia. The mortality rate attributable to invasive aspergillosis was 27%, confirming previous reports of a downward trend in this rate. Univariate and multivariate analyses revealed that the stage of acute myeloid leukemia and the duration of, and recovery from, neutropenia were independent prognostic factors. We analyzed outcomes after treatment with the three most frequently used drugs (liposomal amphotericin B, caspofungin, voriconazole). No differences emerged in survival at day 120 or in the overall response rate which was 71%, ranging from 61% with caspofungin to 84% with voriconazole. CONCLUSIONS: Our series confirms the downward trend in mortality rates reported in previous series, with all new drugs providing similar survival and response rates. Recovery from neutropenia and disease stage are crucial prognostic factors. Efficacious antifungal drugs bridge the period of maximum risk due to poor hematologic and immunological reconstitution.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3324/haematol.2009.012054

Cites

33 of 33 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 33 references

Cited by

See all 316

Metadata

Authors
Pagano, L., Caira, M., Candoni, A., Offidani, M., Martino, B., Specchia, G., Pastore, D., Stanzani, M., Cattaneo, C., Fanci, R., Caramatti, C., Rossini, F., Luppi, M., Potenza, L., Ferrara, F., Mitra, M. E., Fadda, R. M., Invernizzi, R., Aloisi, T., Picardi, M., Bonini, A., Vacca, A., Chierichini, A., Melillo, L., de Waure, C., Fianchi, L., Riva, M., Leone, G., Aversa, F., & Nosari, A.
Venue
Haematologica
Published
2009-10-22
Volume
95
Issue
4
Pages
644-650
ISSN
  • 0390-6078 (ISSN-L)
  • 1592-8721
OpenAlex
W2107040094
Cited by
316
References
33
FWCI
13.82
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Invasive aspergillosis in patients with acute myeloid leukemia: a SEIFEM-2008 registry study. https://app.cochat.ai/papers/10.3324/haematol.2009.012054
The paper
Pagano, L., Caira, M., Candoni, A., Offidani, M., Martino, B., Specchia, G., Pastore, D., Stanzani, M., Cattaneo, C., Fanci, R., Caramatti, C., Rossini, F., Luppi, M., Potenza, L., Ferrara, F., Mitra, M. E., Fadda, R. M., Invernizzi, R., Aloisi, T., . . . Nosari, A. (2010). Invasive aspergillosis in patients with acute myeloid leukemia: a SEIFEM-2008 registry study. Haematologica. https://doi.org/10.3324/haematol.2009.012054

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.